MedRegen is a clinical stage pharmaceutical company developing novel therapeutics for the treatment of different types of organ and tissue injury. We aspire to become a leading global pharmaceutical company through scientific discovery and development and bring regenerative medicine to patients across the globe.
Endogenous stem cells within the bone marrow have the unique potential of differentiating into organ specific cell types. Unlike other stem cell therapies that harvest tissue and grow stem cells in the laboratory, MedRegen has developed a novel drug (MRG-001) that is able to mobilize bone marrow derived stem cells to the site of injury through the peripheral circulation to repair injured organs and tissues. Besides stem cells, a number of immunomodulatory cells are mobilized with the ability to suppress inflammation and promote organ repair.
The company’s decades worth of preclinical work has shown a clear improvement in repairing organ injury through MRG-001 administration.
MedRegen LLC is located in Baltimore, Maryland, United States.